Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 7:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 193 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard COVID-19 therapies Clear all
Completed Phase 1Phase 2 Interventional Results available

Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients

NCT04497389
View directory record Official record
Conditions
SARS CoV-2
Interventions
Human Amniotic Fluid
Biological
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 10, 2026, 7:58 AM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19

NCT04440007
View directory record Official record
Conditions
Covid-19
Interventions
Abivertinib, Standard of Care
Drug · Other
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Brandon, Florida • Alexandria, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 10, 2026, 7:58 AM EDT
Withdrawn Phase 2 Interventional

Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore

NCT04350450
View directory record Official record
Conditions
COVID, Coronavirus, COVID-19
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 10, 2026, 7:58 AM EDT
Terminated Phase 2 Interventional Results available

Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection

NCT04335552
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Standard of care, Hydroxychloroquine, Azithromycin
Other · Drug
Lead sponsor
Duke University
Other
Eligibility
12 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 10, 2026, 7:58 AM EDT
Completed Not applicable Interventional

UNITE Study (UMN-GE) for COVID-19

NCT04701489
View directory record Official record
Conditions
Covid19, Cytokine Storm, Inflammation
Interventions
Splenic ultrasound
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 10, 2026, 7:58 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection

NCT04508023
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
Rivaroxaban, Placebo, Standard of Care (SOC)
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Oakland, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 10, 2026, 7:58 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19

NCT04527471
View directory record Official record
Conditions
Coronavirus Infection, Covid-19, SARS-CoV-2
Interventions
Ensifentrine Dose 1, Placebo pMDI
Drug
Lead sponsor
Verona Pharma Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 10, 2026, 7:58 AM EDT
Completed Phase 3 Interventional Results available

Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)

NCT04546581
View directory record Official record
Conditions
COVID, COVID-19, SARS-CoV-2, SARS (Severe Acute Respiratory Syndrome)
Interventions
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo, Remdesivir
Biological · Other · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Colorado Springs, Colorado • Lakewood, Colorado • Westminster, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 10, 2026, 7:58 AM EDT
Completed Phase 3 Interventional

Multi-site Adaptive Trials for COVID-19

NCT04370262
View directory record Official record
Conditions
COVID-19
Interventions
SOC + Intravenous Famotidine, SOC + Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Bay Shore, New York • Manhasset, New York • Mount Kisco, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 10, 2026, 7:58 AM EDT
Completed Not applicable Interventional Results available

Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19

NCT05419128
View directory record Official record
Conditions
Alcohol Use Disorder, Family Members, Behavior, Addictive
Interventions
PartnerCHESS, ACHESS
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 10, 2026, 7:58 AM EDT
Withdrawn Phase 3 Interventional

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

NCT04361552
View directory record Official record
Conditions
Cerebrovascular Accident, Chronic Obstructive Pulmonary Disease, Chronic Renal Failure, Coronary Artery Disease, Diabetes Mellitus, Malignant Neoplasm, SARS Coronavirus 2 Infection
Interventions
Best Practice, Tocilizumab
Other · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 10, 2026, 7:58 AM EDT
Terminated Not applicable Interventional

Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)

NCT04397692
View directory record Official record
Conditions
Corona Virus Infection, COVID-19, SARS-CoV 2, Nitric Oxide, Respiratory Disease, Pneumonia, Viral, Inhaled Nitric Oxide
Interventions
Nitric Oxide delivered via LungFit™ system
Device
Lead sponsor
Beyond Air Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2022 · Synced Oct 10, 2026, 7:58 AM EDT
Completed Phase 1 Interventional

Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation

NCT04456452
View directory record Official record
Conditions
COVID-19
Interventions
Ampion, Standard of Care
Biological · Other
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 10, 2026, 7:58 AM EDT
Completed Phase 2 Interventional Results available

Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)

NCT04583592
View directory record Official record
Conditions
COVID-19
Interventions
Camostat Mesilate, Placebo
Drug
Lead sponsor
Sagent Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
21
States / cities
Palm Springs, California • Bradenton, Florida • Brandon, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 10, 2026, 7:58 AM EDT
Terminated Phase 2 Interventional Results available

Inhaled Nitric Oxide for Preventing Progression in COVID-19

NCT04388683
View directory record Official record
Conditions
COVID-19
Interventions
Nitric Oxide
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 10, 2026, 7:58 AM EDT
Completed Not applicable Interventional

Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 COVID-19 (COVI-PRONE)

NCT04350723
View directory record Official record
Conditions
Corona Virus Infection, Covid19, COVID-19
Interventions
Awake Proning
Procedure
Lead sponsor
St. Joseph's Healthcare Hamilton
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 10, 2026, 7:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

COVID-19 and the Healthy Minds Program for Educators

NCT04426318
View directory record Official record
Conditions
Anxiety, Depression, Psychological Stress, Psychological Distress, Well-being
Interventions
Healthy Minds Program Foundations Training
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 10, 2026, 7:58 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia

NCT04467840
View directory record Official record
Conditions
COVID-19, Lung Infection
Interventions
Opaganib, Placebo
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 10, 2026, 7:58 AM EDT
Not listed Not applicable Interventional

UNITE Study (UCSD-SW) for COVID-19

NCT04803409
View directory record Official record
Conditions
Covid19
Interventions
Splenic Ultrasound
Device
Lead sponsor
Imanuel Lerman
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 10, 2026, 7:58 AM EDT
Not listed No phase listed Observational

Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease

NCT05014555
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
GI Alliance
Other
Eligibility
18 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Jacksonville, Florida • Baton Rouge, Louisiana • Southlake, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 10, 2026, 7:58 AM EDT
Completed Phase 4 Interventional Results available

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

NCT04505774
View directory record Official record
Conditions
Covid19
Interventions
theraputic heparin, prophylactic heparin, P2Y12, Crizanlizumab Injection, SGLT2 inhibitor
Drug
Lead sponsor
Matthew Neal MD
Other
Eligibility
18 Years and older
Enrollment
3,591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
81
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Oct 10, 2026, 7:58 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)

NCT04480424
View directory record Official record
Conditions
COVID-19
Interventions
GAMUNEX-C, Standard Medical Treatment
Biological · Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Chandler, Arizona • Coronado, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 10, 2026, 7:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cold Plasma for Dental Restoration and Caries Prevention

NCT01529606
View directory record Official record
Conditions
Dental Restoration, Caries
Interventions
Composite restoration and tooth cleaning, Plasma treatment
Other · Procedure
Lead sponsor
Nanova, Inc
Industry
Eligibility
18 Years to 35 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 10, 2026, 7:58 AM EDT
Terminated Not applicable Interventional Results available

AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19

NCT04649775
View directory record Official record
Conditions
Corona Virus Infection, Respiratory Rate, Hypoxia, Covid19
Interventions
AirFLO2
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 10, 2026, 7:58 AM EDT